ClinicalTrials.gg
RecruitingNCT06999590Updated Sep 23, 2026

Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers

A Phase 4 interventional study of ACApatch™ and caregraFT™ in Pressure Ulcer, Ulcer and Ulcer, Pressure, sponsored by Tiger Biosciences, LLC.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Tiger Biosciences, LLC. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.
Phase
Phase 4
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study it to evaluate several cellular, acellular, and matrix-like products (CAMPs) and standard of care versus matched standard of care controls in the management of nonhealing pressure ulcers.

Read the detailed description

To determine the between-arm difference in the proportion of subjects achieving complete closure of nonhealing pressure ulcers with multiple CAMPs plus SOC versus matched SOC controls (mSOC) over 20 weeks using a modified platform trial design. The initial plan is to evaluate two CAMPs; however, the modified platform design permits the inclusion of additional CAMPs.

02

Conditions studied

  • Pressure Ulcer
  • Ulcer
  • Ulcer, Pressure
  • Pressure Injury
03

In context

Pressure Ulcer

545 studies on the registry are indexed under Pressure Ulcer; 129 are open to participants now.

This study's planned enrollment of 500 is above the median of 70 across 405 interventional studies indexed under Pressure Ulcer.

Browse Pressure Ulcer studies →

Lead sponsor

Tiger Biosciences, LLC. is the lead sponsor of 9 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The potential subject must be at least 18 years of age or older.
  2. The potential subject must agree to attend the weekly study visits required by the protocol.
  3. The potential subject must be willing and able to participate in the process.
  4. The potential subject must have a full-thickness pressure ulcer NPIAP stage 3 or stage 4 without exposed tendon or bone of greater than or equal to one month in duration located on the trunk (sacral, trochanteric, or ischial).
  5. At enrollment, the potential subject must have a target ulcer with a minimum surface area of 2 cm2 and a maximum surface area of 100 cm2 measured post-debridement with the imaging device.
  6. The potential subject has adequate off-loading of the ulcer.

Exclusion criteria

Exclusion Criteria:

  1. The potential subject is known to have a of \< 3 months.
  2. The potential subject's target ulcer is not a pressure ulcer.
  3. The target ulcer is infected, requires systemic antibiotic therapy, or there is cellulitis in the surrounding skin.
  4. The target ulcer exposes tendon or bone.
  5. The target ulcer has undermining or tunneling.
  6. There is evidence of osteomyelitis complicating the target ulcer.
  7. The potential subject is receiving (including systemic at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).
  8. The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.
  9. The potential subject has (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.
  10. The surface area of the potential subject's target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit ("historical" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).
  11. The surface area measurement of the potential subject's target ulcer decreases by 25% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (S1) to the TV-1 visit during which time the potential subject received SOC.
  12. The potential subject is a woman who is pregnant or considering becoming pregnant within the next 6 months.
  13. The potential subject has end stage renal disease requiring dialysis.
  14. The potential subject, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.
  15. The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit.
  16. The potential subject has a malnutrition indicator score of \<17 as measured on the Mini Nutritional Assessment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    ACApatch™ + SOC

    Human amniotic membrane tissue allografts derived from human placental tissue.

    Other: ACApatch™

  • Experimental
    caregraFT™ + SOC

    Human amniotic membrane tissue allografts derived from human placental tissue.

    Other: caregraFT™

  • Active comparator
    Standard of Care

    Standard of care will be cleaning, debridement, and ulcer moisture balance.

    Other: Standard of Care

Interventions

  • OtherACApatch™

    Participants will receive weekly applications of ACApatch™ and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first.

  • OthercaregraFT™

    Participants will receive weekly applications of caregraFT™ and Standard of Care until ulcer closure, or a maximum of 20 weeks, whichever occurs first.

  • OtherStandard of Care

    Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance) until ulcer closure, or a maximum of 20 weeks, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. Complete closure

    To determine the between-arm difference in the proportion of subjects achieving complete closure of nonhealing pressure ulcers with multiple CAMPs plus SOC versus matched SOC controls (mSOC) over 20 weeks using a modified platform trial design.

    Time frame: 1-20 Weeks

Secondary outcomes

  1. Time to Closure

    To determine the between-arm difference in the time to closure over 16 weeks for CAMP plus SOC versus mSOC.

    Time frame: 1-20 weeks

  2. Percentage Area Reduction

    To determine the between-arm difference in the percent area reduction (PAR) at weekly intervals the CAMP plus SOC arms versus mSOC.

    Time frame: 1-20 weeks

  3. Determine Quality of Life

    To determine the between-arm difference in pain for patients that present with a VAS score of greater than 4. Pain will be rated on a scale of 0 to 10, with 0 meaning no pain and 10 meaning the most pain.

    Time frame: 1-20 weeks

  4. Adverse Events

    To evaluate the between-arm difference in the frequency and nature of adverse events in subjects receiving CAMP plus SOC versus mSOC.

    Time frame: 1-20 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06999590
Lead sponsor
Tiger Biosciences, LLC.
Collaborators
SerenaGroup, Inc.
Responsible party
Sponsor
First posted
May 31, 2025
Start date
May 20, 2025
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Sep 23, 2026

Study contacts

Arshdeep Kaur, MS
Contact
arshdeepk@tigerbios.com
1-888-665-5005
Khristina Harrel
Contact
kharrell@serenagroups.com
1-412-212-0123
Thomas Serena, MD
principal investigator · Serena Group

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion